Evaluating  	Evaluating  	 VBG	O
temsirolimus  	temsirolimus  	 JJ	B-NP
activity  	activity  	 NN	I-NP
in  	in  	 IN	O
multiple  	multiple  	 JJ	O
tumors 	tumors 	 NNS	O
:  	:  	 :	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
Activation  	Activation  	 NNP	I-NP
of  	of  	 IN	I-NP
mammalian  	mammalian  	 JJ	I-NP
target  	target  	 NN	I-NP
of  	of  	 IN	I-NP
rapamycin  	rapamycin  	 NNS	I-NP
( 	( 	 -LRB-	O
mTOR 	mTOR 	 NNP	B-NP
)  	)  	 -RRB-	O
signaling  	signaling  	 NN	O
occurs  	occurs  	 VBZ	O
in  	in  	 IN	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
variety  	variety  	 NN	O
of  	of  	 IN	O
human  	human  	 JJ	O
tumors  	tumors  	 NNS	O
and  	and  	 CC	O
can  	can  	 MD	O
lead  	lead  	 VB	O
to  	to  	 TO	O
increased  	increased  	 VB	O
susceptibility  	susceptibility  	 VBN	O
to  	to  	 TO	O
mTOR  	mTOR  	 JJ	B-NP
inhibitors 	inhibitors 	 NN	I-NP
.  	.  	 .	O
Temsirolimus 	Temsirolimus 	 NNP	B-NP
,  	,  	 ,	O
a  	a  	 DT	O
novel  	novel  	 NN	O
analog  	analog  	 NN	O
of  	of  	 IN	O
rapamycin 	rapamycin 	 NN	B-NP
,  	,  	 ,	O
has  	has  	 VBZ	O
shown  	shown  	 VBN	O
promising  	promising  	 JJ	O
preclinical  	preclinical  	 NN	B-NP
and  	and  	 CC	O
early  	early  	 JJ	O
clinical  	clinical  	 JJ	B-NP
anti-tumor  	anti-tumor  	 JJ	I-NP
activity  	activity  	 NN	I-NP
in  	in  	 IN	O
various  	various  	 JJ	O
solid  	solid  	 JJ	O
and  	and  	 CC	O
hematologic  	hematologic  	 JJ	B-NP
tumor  	tumor  	 NN	I-NP
types 	types 	 NNS	I-NP
,  	,  	 ,	O
either  	either  	 CC	O
alone  	alone  	 RB	O
or  	or  	 CC	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
chemotherapy  	chemotherapy  	 NN	O
or  	or  	 CC	O
other  	other  	 JJ	O
targeted  	targeted  	 JJ	O
agents 	agents 	 NNS	O
.  	.  	 .	O
Randomized  	Randomized  	 JJ	B-NP
phase  	phase  	 NN	I-NP
III  	III  	 NNP	I-NP
trials  	trials  	 NNS	O
have  	have  	 VBP	O
already  	already  	 RB	O
demonstrated  	demonstrated  	 VBN	O
significant  	significant  	 JJ	O
clinical  	clinical  	 JJ	B-NP
benefits  	benefits  	 NNS	I-NP
of  	of  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
single-agent  	single-agent  	 JJ	B-NP
temsirolimus  	temsirolimus  	 NN	I-NP
in  	in  	 IN	O
advanced  	advanced  	 JJ	O
renal  	renal  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NNS	I-NP
and  	and  	 CC	O
relapsed  	relapsed  	 NNS	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
refractory  	refractory  	 JJ	B-NP
mantle  	mantle  	 JJ	I-NP
cell  	cell  	 NN	I-NP
lymphoma 	lymphoma 	 NN	I-NP
.  	.  	 .	O
Other  	Other  	 JJ	O
malignancies  	malignancies  	 NNS	O
studied  	studied  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
phase  	phase  	 NN	O
I  	I  	 PRP	O
and  	and  	 CC	O
II  	II  	 NNP	O
trial  	trial  	 NN	B-NP
settings  	settings  	 NNS	I-NP
include  	include  	 VBP	O
glioblastoma 	glioblastoma 	 VBN	O
,  	,  	 ,	O
breast  	breast  	 JJ	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
endometrial  	endometrial  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
,  	,  	 ,	O
non-Hodgkin  	non-Hodgkin  	 JJ	B-NP
lymphomas 	lymphomas 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
multiple  	multiple  	 JJ	O
myeloma 	myeloma 	 NN	B-NP
.  	.  	 .	O
This  	This  	 DT	O
article  	article  	 NN	O
reviews  	reviews  	 VBZ	O
a  	a  	 DT	O
comprehensive  	comprehensive  	 JJ	B-NP
collection  	collection  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
clinical  	clinical  	 JJ	I-NP
trial  	trial  	 NN	I-NP
results  	results  	 NNS	I-NP
reported  	reported  	 VBD	O
to  	to  	 TO	O
date  	date  	 NN	O
for  	for  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
in  	in  	 IN	O
various  	various  	 JJ	O
solid  	solid  	 JJ	O
and  	and  	 CC	O
hematologic  	hematologic  	 JJ	B-NP
malignancies 	malignancies 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
current  	current  	 JJ	O
strategies  	strategies  	 NNS	O
being  	being  	 VBG	O
tested  	tested  	 VBN	O
in  	in  	 IN	O
ongoing  	ongoing  	 JJ	O
trials 	trials 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
findings  	findings  	 NNS	O
with  	with  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
in  	in  	 IN	O
multiple  	multiple  	 JJ	O
tumors  	tumors  	 NNS	O
provide  	provide  	 VBP	O
a  	a  	 DT	O
valuable  	valuable  	 JJ	O
framework  	framework  	 NN	O
for  	for  	 IN	O
future  	future  	 JJ	O
development  	development  	 NN	O
of  	of  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
and  	and  	 CC	O
other  	other  	 JJ	O
mTOR  	mTOR  	 JJ	B-NP
inhibitors 	inhibitors 	 NN	I-NP
.  	.  	 .	O
